TY  - JOUR
A1  - Kunath, Frank
A1  - Krause, Steffen F.
A1  - Wullich, Bernd
A1  - Goebell, Peter J.
A1  - Engehausen, Dirk G.
A1  - Burger, Maximilian
A1  - Meerpohl, Joerg J.
A1  - Keck, Bastian
T1  - Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov
JF  - BMC Urology
N2  - Background: Uro-oncological neoplasms have both a high incidence and mortality rate and are therefore a major public health problem. The aim of this study was to evaluate research activity in uro-oncology over the last decade. 
Methods: We searched MEDLINE and ClinicalTrials.gov systematically for studies on prostatic, urinary bladder, kidney, and testicular neoplasms. The increase in newly published reports per year was analyzed using linear regression. The results are presented with 95% confidence intervals, and a p value <0.05 was considered statistically significant. 
Results: The number of new publications per year increased significantly for prostatic, kidney and urinary bladder neoplasms (all <0.0001). We identified 1,885 randomized controlled trials (RCTs); also for RCTs, the number of newly published reports increased significantly for prostatic (p = 0.001) and kidney cancer (p = 0.005), but not for bladder (p = 0.09) or testicular (p = 0.44) neoplasms. We identified 3,114 registered uro-oncological studies in ClinicalTrials.gov. However, 85% of these studies are focusing on prostatic (45%) and kidney neoplasms (40%), whereas only 11% were registered for bladder cancers. 
Conclusions: While the number of publications on uro-oncologic research rises yearly for prostatic and kidney neoplasms, urothelial carcinomas of the bladder seem to be neglected despite their important clinical role. Clinical research on neoplasms of the urothelial bladder must be explicitly addressed and supported.
KW  - update
KW  - kidney neoplasms
KW  - prostatic neoplasms
KW  - randomized controlled trial
KW  - testicular neoplasms
KW  - surgery
KW  - journals
KW  - EAU guidelines
KW  - radical cystectomy
KW  - urinary bladder neoplasms
KW  - controlled clinical-trials
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-122133
VL  - 13
IS  - 56
ER  - 
TY  - JOUR
A1  - Al-Janabi, Omar
A1  - Taubert, Helge
A1  - Lohse-Fischer, Andrea
A1  - Fröhner, Michael
A1  - Wach, Sven
A1  - Stöhr, Robert
A1  - Keck, Bastian
A1  - Burger, Max
A1  - Wieland, Wolf
A1  - Erdmann, Kati
A1  - Wirth, Manfred P.
A1  - Wullich, Bernd
A1  - Baretton, Gustavo
A1  - Magdolen, Viktor
A1  - Kotzsch, Mathias
A1  - Füssel, Susanne
T1  - Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
JF  - Biomed Research International
N2  - The objective was to determine the mRNA expression and protein levels of uPA system components in tissue specimens and serum samples, respectively, from prostate cancer (PCa) patients and to assess their association with clinicopathological parameters and overall survival (OS). The mRNA expression levels of uPA, its receptor (uPAR), and its inhibitor type 1 (PAI-1) were analyzed in corresponding malignant and adjacent nonmalignant tissue specimens from 132 PCa patients by quantitative PCR. Preoperative serum samples from 81 PCa patients were analyzed for antigen levels of uPA system members by ELISA. RNA levels of uPA system components displayed significant correlations with each other in the tumor tissues. A significantly decreased uP AmRNA expression in PCa compared to the corresponding nonmalignant tissue was detected. High uPA mRNA level was significantly associated with a high Gleason score. Elevated concentration of soluble uPAR (suPAR) in serum was significantly associated with a poor OS of PCa patients (P = 0.022). PCa patients with high suPAR levels have a significantly higher risk of death (multivariate Cox's regression analysis; IIR - 7.12, P - 0.027). The association of high suPAR levels with poor survival of PCa patients suggests a prognostic impact of suPAR levels in serum of cancer patients.
KW  - receptor splice variant
KW  - primary breast cancer
KW  - radical prostatectomy
KW  - tumor tissue
KW  - progression
KW  - potential marker
KW  - inhibitor PAI-1
KW  - gastric cancer
KW  - biomarkers UPA
KW  - expression
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117967
SN  - 2314-6141
IS  - 972587
ER  -